Adaptive Biotechnologies (ADPT) Interest Expenses (2022 - 2026)

Adaptive Biotechnologies has disclosed Interest Expenses across 5 years of filings, most recently posting $2.9 million for Q1 2026.

• Interest Expenses for Q1 2026 came in at $2.9 million, down 0.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.8 million (up 2.35% YoY), and the FY2025 annual result was $11.8 million, up 1.71% from the prior year.
• Interest Expenses came in at $2.9 million for Q1 2026 at Adaptive Biotechnologies, down from $3.0 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $3.7 million in Q3 2023 to a low of $653000.0 in Q3 2022.
• The 5-year median for Interest Expenses is $3.0 million (2025), against an average of $3.0 million.
• Across the five-year window, Interest Expenses jumped 459.26% in 2023 and dropped 25.21% in 2024, its largest moves.
• Adaptive Biotechnologies' Interest Expenses stood at $3.6 million in 2022, then dropped by 15.98% to $3.0 million in 2023, then retreated by 1.99% to $3.0 million in 2024, then gained by 0.07% to $3.0 million in 2025, then slipped by 2.2% to $2.9 million in 2026.
• The last three Interest Expenses figures came in at $2.9 million (Q1 2026), $3.0 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.